3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
5
Active not recruiting
2
Withdrawn
1
Terminated
1
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Endocrine
4
NET
3
CNS
2
Head & Neck
1
Gastrointestinal
1
Conditions
Neuroendocrine Tumors
1
Gastro-enteropancreatic neuroendocrine tumor
1
Interventions
Fluorouracil
51
Oxaliplatin
49
Gemcitabine
47
Leucovorin
41
Capecitabine
35
Bevacizumab
29
Irinotecan
25
Cisplatin
22
Radiotherapy
18
Radiosurgery
18
pembrolizumab
16
Nivolumab
16
Cetuximab
15
Taxes
14
Sorafenib
14
Paclitaxel
13
Biopsy
13
Surgical Procedures, Operative
12
Drug Therapy
11
atezolizumab
10
Radiation
10
Albumin-Bound Paclitaxel
10
lenvatinib
9
durvalumab
9
Magnetic Resonance Spectroscopy
9
Folfox protocol
9
Cyclophosphamide
9
130-nm albumin-bound paclitaxel
9
spartalizumab
8
Chemotherapy, Adjuvant
8
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Withdrawn
×
lutetium Lu 177 dotatate
×
Gastrointestinal
×
Clear all
NCT04614766
2024-04-29
SPORE-3
University of Iowa
Phase 1/2
Withdrawn